Chronic heart failure (CHF) is a complex and progressive clinical syndrome characterized by the heart's inability to meet the metabolic demands of the body. Despite advances in pharmacologic and device-based therapies, CHF continues to be associated with high morbidity and mortality rates worldwide. This paper presents a comprehensive review of current diagnostic approaches and evolving treatment strategies for CHF, with a focus on guideline-directed medical therapy (GDMT), novel pharmacological agents, non-pharmacological interventions, and the importance of multidisciplinary care models. Emerging technologies in diagnostics such as cardiac imaging, biomarkers, and digital monitoring tools are also discussed. The goal is to provide a structured framework for clinicians aiming to improve patient outcomes through evidence-based management protocols.The paper includes statistical analysis and visual representation of patient data over the years to underline the growing burden of CHF
Chronic heart failure (CHF) is a complex and progressive clinical syndrome characterized by the heart's inability to meet the metabolic demands of the body. Despite advances in pharmacologic and device-based therapies, CHF continues to be associated with high morbidity and mortality rates worldwide. This paper presents a comprehensive review of current diagnostic approaches and evolving treatment strategies for CHF, with a focus on guideline-directed medical therapy (GDMT), novel pharmacological agents, non-pharmacological interventions, and the importance of multidisciplinary care models. Emerging technologies in diagnostics such as cardiac imaging, biomarkers, and digital monitoring tools are also discussed. The goal is to provide a structured framework for clinicians aiming to improve patient outcomes through evidence-based management protocols.The paper includes statistical analysis and visual representation of patient data over the years to underline the growing burden of CHF
| № | Author name | position | Name of organisation |
|---|---|---|---|
| 1 | Ikramova A.S. | ! | Tashkent State Medical University |
| 2 | Jabbarova A.M. | ! | Tashkent State Medical University |
| 3 | Ubaydullaeva B.N. | ! | Tashkent State Medical University |
| № | Name of reference |
|---|---|
| 1 | 1.Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016;37(27):2129-2200.2.McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-3726.3.Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 Guidelines for the Management of Heart Failure. Journal of the American College of Cardiology. 2017;70(6):776-803.4.Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. NEJM. 2011;364(1):11-21.5.Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2022;79(17):e263-e421.6.Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. NEJM. 2020;383(15):1413–1424.7.McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. NEJM. 2019;381(21):1995–2008. |